Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
21.92
-0.56 (-2.49%)
At close: Apr 28, 2026, 4:00 PM EDT
21.92
0.00 (0.00%)
Pre-market: Apr 29, 2026, 4:12 AM EDT
Bicara Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Net Income | -137.95 | -68 | -51.99 | -37.85 |
| Depreciation & Amortization | 0.11 | 0.06 | 0.02 | 0.01 |
| Asset Writedown & Restructuring Costs | - | - | 0.57 | - |
| Loss (Gain) From Sale of Investments | 0.3 | - | - | - |
| Stock-Based Compensation | 15.01 | 7.4 | 1.9 | 0.81 |
| Other Operating Activities | 0.9 | -0.08 | 13.5 | - |
| Change in Accounts Payable | 10.46 | 2.64 | -8.66 | 5.87 |
| Change in Other Net Operating Assets | 4.35 | -16.77 | -0.96 | -0.92 |
| Operating Cash Flow | -106.83 | -74.75 | -45.63 | -32.08 |
| Capital Expenditures | -0.28 | -0.07 | -0.59 | -0.19 |
| Sale of Property, Plant & Equipment | - | 0.06 | - | - |
| Investment in Securities | -318.17 | - | - | - |
| Investing Cash Flow | -318.45 | -0.01 | -0.59 | -0.19 |
| Issuance of Common Stock | 32.26 | 334.03 | 0.15 | 0.16 |
| Financing Cash Flow | 32.26 | 334.03 | 272.5 | 31.7 |
| Net Cash Flow | -393.03 | 259.27 | 226.28 | -0.57 |
| Free Cash Flow | -107.11 | -74.82 | -46.21 | -32.27 |
| Free Cash Flow Per Share | -1.96 | -4.45 | -79.66 | -75.20 |
| Cash Income Tax Paid | - | - | - | 0 |
| Levered Free Cash Flow | -66.4 | -53.72 | -32.5 | - |
| Unlevered Free Cash Flow | -66.4 | -53.72 | -32.5 | - |
| Change in Working Capital | 14.81 | -14.13 | -9.62 | 4.95 |
Source: S&P Capital IQ. Standard template.
Financial Sources.